<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT2016022821653N5</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2016-10-25</date_registration>
      <primary_sponsor>Vice Chancellor for research of jahrom university of medical sience</primary_sponsor>
      <public_title>The influence of vitamin D and vitamin E  in the treatment of infertile women with polycystic ovary syndrome</public_title>
      <acronym></acronym>
      <scientific_title>Assessing the effect of  adding vitamin D and vitamin E to metformin with dydrogesterone   regimen؛  in the treatment of infertile women with  polycystic ovary syndrome</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2016-06-21</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>317</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/18910</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Other design features: Table of random numbers for choosing patients.</study_design>
      <phase>3</phase>
      <hc_freetext>Polycystic ovary syndrome.</hc_freetext>
      <i_freetext>Intervention 1: intervention group 3: metformin 500mg by Shafa pharmaceuticals؛ one tablet  daily for the first week؛  two tablets  daily for the second week and then three tablets daily from the third week to the rest of therapy for three months. tablet Dydrogesterone 10mg by solvay pharmaceuticals one tablet daily from the fifteenth day of menstrual cycle to the twenty fifth day of it for three months.tablet vitamin E 400mg from Dana pharmaceuticals one tablet daily for three months.&#13;
control group 3: only  metformin 500mg by Shafa pharmaceuticals؛ one tablet  daily for the first week؛  two tablets  daily for the second week and then three tablets daily from the third week to the rest of therapy for three months. tablet Dydrogesterone 10mg by solvay pharmaceuticals one tablet daily from the fifteenth day of menstrual cycle to the twenty fifth day of it for three months. Intervention 2: intervention group 2: metformin 500mg by Shafa pharmaceuticals؛ one tablet  daily for the first week؛  two tablets  daily for the second week and then three tablets daily from the third week to the rest of therapy for three months. tablet Dydrogesterone 10mg by solvay pharmaceuticals one tablet daily from the fifteenth day of menstural cycle to the twenty fifth day of it for three months. capsule vitamin D1000IU from Zahravy pharmaceuticals one capsule daily for three months.&#13;
control group 2: only  metformin 500mg by Shafa pharmaceuticals؛ one tablet  daily for the first week؛  two tablets  daily for the second week and then three tablets daily from the third week to the rest of therapy for three months. tablet Dydrogesterone 10mg by solvay pharmaceuticals one tablet daily from the fifteenth day of menstural cycle to the twenty fifth day of it for three months. Intervention 3: intervention group 1: metformin 500mg by Shafa pharmaceuticals؛ one tablet  daily for the first week؛  two tablets  daily for the second week and then three tablets daily from the third week to the rest of therapy for three months. tablet Dydrogesterone 10mg by solvay pharmaceuticals one tablet daily from the fifteenth day of menstrual cycle to the twenty fifth day of it for three months. capsule vitamin D1000IU from Zahravy pharmaceuticals one capsule daily for three months.&#13;
control group 1: only  metformin 500mg by Shafa pharmaceuticals؛ one tablet  daily for the first week؛  two tablets  daily for the second week and then three tablets daily from the third week to the rest of therapy for three months. tablet Dydrogesterone 10mg by solvay pharmaceuticals one tablet daily from the fifteenth day of menstrual cycle to the twenty fifth day of it for three months. Intervention 4: intervention group4: metformin 500mg by Shafa pharmaceuticals؛ one tablet  daily for the first week؛  two tablets  daily for the second week and then three tablets daily from the third week to the rest of therapy for three months. tablet Dydrogesterone 10mg by solvay pharmaceuticals one tablet daily from the fifteenth day of menstrual cycle to the twenty fifth day of it for three months.tablet vitamin E 400mg from Dana pharmaceuticals one tablet daily for three months.&#13;
control group 4: only  metformin 500mg by Shafa pharmaceuticals؛ one tablet  daily for the first week؛  two tablets  daily for the second week and then three tablets daily from the third week to the rest of therapy for three months. tablet Dydrogesterone 10mg by solvay pharmaceuticals one tablet daily from the fifteenth day of menstrual cycle to the twenty fifth day of it for three months.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan></results_IPD_plan>
      <results_IPD_description></results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Dr Kavous Solhjo</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Jahrom University of Medical Sience, Motahari boulevard</address>
        <city>Jahrom</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip></zip>
        <telephone>+98 71 5444 0821</telephone>
        <email>sohjo@jums.ac.ir</email>
        <affiliation>Jahrom University of Medical Sience</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Fatemeh Kargarfard</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Alley 5. Fard asadi avenue</address>
        <city>Jahrom</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>7416653134</zip>
        <telephone>+7 1330990</telephone>
        <email>fatemehkargarfard@yahoo.com</email>
        <affiliation>Jahrom University of Medical Sience</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Inclusion criteria؛ Infertile women with polycystic ovary syndrome (PCOS)؛  which  had  no pregnancy  history after 12 months of unprotected intercourse.&#13;
 Exclusion criteria؛  Women with other causes of infertility such as endometriosis؛ internal and  surgical diseases؛  and patients who do not  have polycystic ovary syndrome (PCOS) criteria.</inclusion_criteria>
      <agemin>no limit</agemin>
      <agemax>no limit</agemax>
      <gender>Female</gender>
      <exclusion_criteria></exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>E28.2</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Polycystic ovary syndrome</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>intervention group 3: metformin 500mg by Shafa pharmaceuticals؛ one tablet  daily for the first week؛  two tablets  daily for the second week and then three tablets daily from the third week to the rest of therapy for three months. tablet Dydrogesterone 10mg by solvay pharmaceuticals one tablet daily from the fifteenth day of menstrual cycle to the twenty fifth day of it for three months.tablet vitamin E 400mg from Dana pharmaceuticals one tablet daily for three months.&#13;
control group 3: only  metformin 500mg by Shafa pharmaceuticals؛ one tablet  daily for the first week؛  two tablets  daily for the second week and then three tablets daily from the third week to the rest of therapy for three months. tablet Dydrogesterone 10mg by solvay pharmaceuticals one tablet daily from the fifteenth day of menstrual cycle to the twenty fifth day of it for three months.</i_keyword>
      <i_keyword>intervention group 2: metformin 500mg by Shafa pharmaceuticals؛ one tablet  daily for the first week؛  two tablets  daily for the second week and then three tablets daily from the third week to the rest of therapy for three months. tablet Dydrogesterone 10mg by solvay pharmaceuticals one tablet daily from the fifteenth day of menstural cycle to the twenty fifth day of it for three months. capsule vitamin D1000IU from Zahravy pharmaceuticals one capsule daily for three months.&#13;
control group 2: only  metformin 500mg by Shafa pharmaceuticals؛ one tablet  daily for the first week؛  two tablets  daily for the second week and then three tablets daily from the third week to the rest of therapy for three months. tablet Dydrogesterone 10mg by solvay pharmaceuticals one tablet daily from the fifteenth day of menstural cycle to the twenty fifth day of it for three months.</i_keyword>
      <i_keyword>intervention group 1: metformin 500mg by Shafa pharmaceuticals؛ one tablet  daily for the first week؛  two tablets  daily for the second week and then three tablets daily from the third week to the rest of therapy for three months. tablet Dydrogesterone 10mg by solvay pharmaceuticals one tablet daily from the fifteenth day of menstrual cycle to the twenty fifth day of it for three months. capsule vitamin D1000IU from Zahravy pharmaceuticals one capsule daily for three months.&#13;
control group 1: only  metformin 500mg by Shafa pharmaceuticals؛ one tablet  daily for the first week؛  two tablets  daily for the second week and then three tablets daily from the third week to the rest of therapy for three months. tablet Dydrogesterone 10mg by solvay pharmaceuticals one tablet daily from the fifteenth day of menstrual cycle to the twenty fifth day of it for three months.</i_keyword>
      <i_keyword>intervention group4: metformin 500mg by Shafa pharmaceuticals؛ one tablet  daily for the first week؛  two tablets  daily for the second week and then three tablets daily from the third week to the rest of therapy for three months. tablet Dydrogesterone 10mg by solvay pharmaceuticals one tablet daily from the fifteenth day of menstrual cycle to the twenty fifth day of it for three months.tablet vitamin E 400mg from Dana pharmaceuticals one tablet daily for three months.&#13;
control group 4: only  metformin 500mg by Shafa pharmaceuticals؛ one tablet  daily for the first week؛  two tablets  daily for the second week and then three tablets daily from the third week to the rest of therapy for three months. tablet Dydrogesterone 10mg by solvay pharmaceuticals one tablet daily from the fifteenth day of menstrual cycle to the twenty fifth day of it for three months.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Follicle  size. Timepoint: Before intervention and 3 months after intervention. Method of measurement: Sonography.</prim_outcome>
      <prim_outcome>Endometrial thickness. Timepoint: Before intervention and 3 months after intervention. Method of measurement: Sonography.</prim_outcome>
      <prim_outcome>Menstural discipline. Timepoint: Before intervention and 3 months after intervention. Method of measurement: Sonography.</prim_outcome>
      <prim_outcome>Pregnancy. Timepoint: Before intervention and 3 months after intervention. Method of measurement: BHCG.</prim_outcome>
      <prim_outcome>Weight. Timepoint: Before intervention and 3 months after intervention. Method of measurement: Scale.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Vice Chancellor for research of jahrom university of medical sience</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2016-02-05</approval_date>
        <contact_name>Jahrom University of Medical Sience</contact_name>
        <contact_address>Jahrom University of Medical Sience. Motahari boulevard Jahrom  Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
